Cargando…
Risk factors contributing to a low darunavir plasma concentration
Darunavir is an efficacious drug; however, pharmacokinetic variability has been reported. The objective of this study was to find predisposing factors for low darunavir plasma concentrations in patients starting the once‐ or twice‐daily dosage. Darunavir plasma concentrations from January 2010 till...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809517/ https://www.ncbi.nlm.nih.gov/pubmed/29077230 http://dx.doi.org/10.1111/bcp.13464 |
_version_ | 1783299576992628736 |
---|---|
author | Daskapan, Alper Stienstra, Ymkje Kosterink, Jos G. W. Bierman, Wouter F. W. van der Werf, Tjip S. Touw, Daan J. Alffenaar, Jan‐Willem C. |
author_facet | Daskapan, Alper Stienstra, Ymkje Kosterink, Jos G. W. Bierman, Wouter F. W. van der Werf, Tjip S. Touw, Daan J. Alffenaar, Jan‐Willem C. |
author_sort | Daskapan, Alper |
collection | PubMed |
description | Darunavir is an efficacious drug; however, pharmacokinetic variability has been reported. The objective of this study was to find predisposing factors for low darunavir plasma concentrations in patients starting the once‐ or twice‐daily dosage. Darunavir plasma concentrations from January 2010 till December 2014 of human immunodeficiency virus‐infected individuals treated in the outpatient clinic of the University Medical Center Groningen were retrospectively reviewed. The first darunavir plasma concentration of patients within 8 weeks after initiation of darunavir therapy was selected. A dichotomous logistic regression analysis was conducted to select the set of variables best predicting a darunavir concentration below median population pharmacokinetic curve. In total 113 patients were included. The variables best predicting a darunavir concentration besides food intake included age together with estimated glomerular filtration rate (Hosmer–Lemeshow test P = 0.945, Nagelkerke R (2) = 0.284). Systematic evaluation of therapeutic drug monitoring results may help to identify patients at risk for low drug exposure. |
format | Online Article Text |
id | pubmed-5809517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58095172018-02-16 Risk factors contributing to a low darunavir plasma concentration Daskapan, Alper Stienstra, Ymkje Kosterink, Jos G. W. Bierman, Wouter F. W. van der Werf, Tjip S. Touw, Daan J. Alffenaar, Jan‐Willem C. Br J Clin Pharmacol Pharmacokinetics Darunavir is an efficacious drug; however, pharmacokinetic variability has been reported. The objective of this study was to find predisposing factors for low darunavir plasma concentrations in patients starting the once‐ or twice‐daily dosage. Darunavir plasma concentrations from January 2010 till December 2014 of human immunodeficiency virus‐infected individuals treated in the outpatient clinic of the University Medical Center Groningen were retrospectively reviewed. The first darunavir plasma concentration of patients within 8 weeks after initiation of darunavir therapy was selected. A dichotomous logistic regression analysis was conducted to select the set of variables best predicting a darunavir concentration below median population pharmacokinetic curve. In total 113 patients were included. The variables best predicting a darunavir concentration besides food intake included age together with estimated glomerular filtration rate (Hosmer–Lemeshow test P = 0.945, Nagelkerke R (2) = 0.284). Systematic evaluation of therapeutic drug monitoring results may help to identify patients at risk for low drug exposure. John Wiley and Sons Inc. 2017-12-07 2018-03 /pmc/articles/PMC5809517/ /pubmed/29077230 http://dx.doi.org/10.1111/bcp.13464 Text en © 2017 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Pharmacokinetics Daskapan, Alper Stienstra, Ymkje Kosterink, Jos G. W. Bierman, Wouter F. W. van der Werf, Tjip S. Touw, Daan J. Alffenaar, Jan‐Willem C. Risk factors contributing to a low darunavir plasma concentration |
title | Risk factors contributing to a low darunavir plasma concentration |
title_full | Risk factors contributing to a low darunavir plasma concentration |
title_fullStr | Risk factors contributing to a low darunavir plasma concentration |
title_full_unstemmed | Risk factors contributing to a low darunavir plasma concentration |
title_short | Risk factors contributing to a low darunavir plasma concentration |
title_sort | risk factors contributing to a low darunavir plasma concentration |
topic | Pharmacokinetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809517/ https://www.ncbi.nlm.nih.gov/pubmed/29077230 http://dx.doi.org/10.1111/bcp.13464 |
work_keys_str_mv | AT daskapanalper riskfactorscontributingtoalowdarunavirplasmaconcentration AT stienstraymkje riskfactorscontributingtoalowdarunavirplasmaconcentration AT kosterinkjosgw riskfactorscontributingtoalowdarunavirplasmaconcentration AT biermanwouterfw riskfactorscontributingtoalowdarunavirplasmaconcentration AT vanderwerftjips riskfactorscontributingtoalowdarunavirplasmaconcentration AT touwdaanj riskfactorscontributingtoalowdarunavirplasmaconcentration AT alffenaarjanwillemc riskfactorscontributingtoalowdarunavirplasmaconcentration |